Spero Therapeutics Announces Underwriters’ Option Exercise
November 13 2017 - 7:00AM
Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset,
clinical-stage biopharmaceutical company focused on identifying,
developing and commercializing novel treatments for multi-drug
resistant bacterial infections, today announced that the
underwriters of its previously announced initial public offering
have exercised their option to purchase an additional 471,498
shares during the option period. Including the option
exercise, total gross proceeds from the offering of an aggregate of
5,971,498 shares were approximately $83.6 million, before deducting
the underwriting discount and estimated offering expenses payable
by Spero. This represents approximately $6.6 million more
gross proceeds than the gross proceeds on the initial
closing. Spero’s common stock began trading on The Nasdaq
Global Select Market on November 2, 2017 under the symbol “SPRO”.
BofA Merrill Lynch, Cowen and Stifel acted as joint book-running
managers for the offering. Oppenheimer & Co. acted as a
co-manager for the offering.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission. The offering was made by means of a prospectus.
Copies of the final prospectus relating to this offering may be
obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College
Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus
Department, or by email at dg.prospectus_requests@baml.com; from
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, or by telephone at (631) 274-2806; and from Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, or by
telephone at (415) 364-2720 or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Spero
Spero Therapeutics, Inc. is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and
commercializing novel treatments for multi-drug resistant bacterial
infections.
Spero Media and Investor Contact
Sharon KlahreDirector, Investor
Relations857-242-1547IR@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Sep 2023 to Sep 2024